GO:0010759 positive regulation of macrophage chemotaxis: Immune Recruitment Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010759 (positive regulation of macrophage chemotaxis) describes any process that increases the rate, frequency, or extent of macrophage-directed migration along an external chemical gradient.
• The process is driven by chemokine-receptor signaling, most prominently the CCL2/CCR2 axis, which recruits monocytes and macrophages into inflamed or tumor tissues.
• Macrophage colony-stimulating factor (CSF1) and its receptor CSF1R, along with interleukin-34 (IL-34), provide a second major recruitment and polarization signal that can be pharmacologically blocked.
• Long non-coding RNAs such as MERRICAL act as epigenetic scaffolds that sustain chemotaxis gene programs, and their loss reduces macrophage recruitment in atherosclerosis.
• Dysregulated positive regulation of macrophage chemotaxis contributes to sepsis-associated acute kidney injury, bladder cancer progression, myocardial ischemia/reperfusion injury, and diabetes-associated atherosclerosis.
• CRISPR knockout, knock-in, and overexpression models combined with chemotaxis assays and RNA-seq are the standard toolkit for dissecting causal genes in this process.
Description
Positive regulation of macrophage chemotaxis (GO:0010759) is the biological process that increases the rate, frequency, or extent of macrophage chemotaxis, meaning the directed movement of a macrophage toward or away from an external chemical stimulus. Macrophages are innate immune cells that must rapidly reposition themselves during infection, tissue repair, and tumor surveillance, and the positive regulation of this migration is what converts a resting tissue macrophage pool into a recruited, functionally engaged population. Because chemotaxis is a rate-limiting step in macrophage accumulation, the molecular players that positively regulate it are attractive targets for anti-inflammatory and immuno-oncology strategies. The process is not a single reaction but an integrated signaling program. Extracellular chemokines such as CCL2 bind G-protein-coupled receptors such as CCR2 on the macrophage surface, triggering actin remodeling and directional motility. Growth-factor signaling through CSF1R and IL-34 receptor complexes reinforces recruitment and simultaneously shapes the polarization state of the arriving cells. Epigenetic and transcriptional regulators, including the histone methyltransferase EZH2 and long non-coding RNAs such as MERRICAL, set the permissive chromatin state that allows chemotaxis genes to be expressed at the required level. For researchers, GO:0010759 matters because it sits at the intersection of immunology, cancer biology, and metabolic disease. Perturbing a single node in this pathway can change macrophage abundance in a tissue, alter tumor immune contexture, or modify injury severity in organs such as kidney and heart. Understanding which genes causally drive positive regulation of macrophage chemotaxis, and which are merely correlated, requires controlled genetic models and quantitative migration assays.
positive regulation of macrophage chemotaxis At A Glance
| GO ID | GO:0010759 |
|---|---|
| GO term | positive regulation of macrophage chemotaxis |
| Ontology | biological_process |
| Synonym | none listed in QuickGO |
| Major function | Increases the rate, frequency, or extent of macrophage chemotaxis in response to an external stimulus |
| Upstream regulators | Chemokines (e.g., CCL2), growth factors (e.g., CSF1, IL-34), and epigenetic modifiers (e.g., EZH2, MERRICAL) |
| Cell type affected | Macrophages, including tissue-resident and tumor-associated macrophages |
| Disease relevance | Sepsis-associated AKI, bladder cancer, myocardial ischemia/reperfusion injury, atherosclerosis, NAFLD/heart failure |
| Experimental readouts | Transwell migration, chemotaxis index, macrophage infiltration by flow cytometry or immunohistochemistry |
What Is GO:0010759?
In our own words, GO:0010759 (positive regulation of macrophage chemotaxis) is any cellular or molecular process that enhances the directed migration of a macrophage in response to an external stimulus. It is a regulatory biological process: it does not itself perform the movement, but it increases the rate, frequency, or extent of the underlying chemotaxis. The term is a child of the broader regulation of macrophage chemotaxis and is defined by its positive effect on macrophage motility toward a chemical cue.
Why Is positive regulation of macrophage chemotaxis Important in Cell Biology?
Positive regulation of macrophage chemotaxis is important because it determines how many macrophages reach a tissue and how quickly they arrive, which in turn shapes the outcome of inflammation, tissue repair, and anti-tumor immunity. When this process is excessive, it can amplify organ injury in sepsis-associated acute kidney injury and myocardial ischemia/reperfusion injury; when it is co-opted by tumors, it supports an immunosuppressive microenvironment that limits T-cell attack. Conversely, loss of positive regulation can impair host defense and tissue remodeling. Because the process is genetically tractable and pharmacologically accessible, it is a high-value area for both mechanistic discovery and therapeutic development.
• Controls the speed and magnitude of macrophage recruitment into inflamed tissues.
• Shapes tumor immune contexture by determining tumor-associated macrophage abundance.
• Contributes to sepsis-associated acute kidney injury through inflammatory macrophage influx.
• Drives monocyte/macrophage recruitment in myocardial ischemia/reperfusion injury via IL-34-NF-kB signaling.
• Is required for diabetes-associated atherosclerosis in models where lncRNA MERRICAL is lost.
• Provides a mechanistic link between chemokine signaling and cancer progression, as shown for the STAT3/CCL2/IL-6 axis in bladder cancer.
• Is modulated by epigenetic regulators such as EZH2, connecting chromatin state to innate immune cell trafficking.
• Can be therapeutically reprogrammed: CSF1R inhibition with pexidartinib alters macrophage recruitment and T-cell infiltration in sarcoma.
• Serves as a readout for M1/M2 polarization states, since recruited macrophages adopt distinct activation signatures.
• Is a tractable target for CRISPR-based causal gene discovery in immunology and oncology.
What Happens During positive regulation of macrophage chemotaxis?
Chemokine sensing and receptor activation
In simple terms: The macrophage first smells the chemical signal and switches on its receptor.
Positive regulation begins when external chemokines such as CCL2 bind to G-protein-coupled receptors such as CCR2 on the macrophage surface. This ligand-receptor engagement is a constitutive and inducible chemokine cooperation that enables immune cell engraftment and attack in solid tumors. In bladder cancer, the STAT3/CCL2/IL-6 axis links cancer cell-macrophage crosstalk to enhanced macrophage recruitment, demonstrating that tumor-derived signals can positively regulate this step. The strength and duration of receptor activation set the threshold for the entire downstream migration program.
Growth-factor and cytokine amplification
In simple terms: A second set of signals makes the macrophage even more responsive and keeps it moving.
CSF1/CSF1R signaling is a major amplifier of macrophage recruitment and survival. Pharmacological inhibition of CSF1R with pexidartinib reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment, showing that this axis positively regulates macrophage presence in tumors. Interleukin-34, which also signals through CSF1R-related complexes, aggravates myocardial ischemia/reperfusion injury by facilitating macrophage recruitment and polarization through NF-kB signaling. These cytokine inputs act in parallel with chemokines to sustain directed migration.
Epigenetic and transcriptional licensing
In simple terms: The cell unlocks the right genes so it can build the migration machinery.
Positive regulation of macrophage chemotaxis requires a permissive transcriptional state. The histone H3K27 methyltransferase EZH2 regulates apoptotic and inflammatory responses in sepsis-induced acute kidney injury, linking chromatin modification to inflammatory macrophage behavior. The long non-coding RNA MERRICAL acts as an epigenetic regulator whose deficiency abrogates macrophage chemotaxis and diabetes-associated atherosclerosis, indicating that non-coding RNA scaffolds are required to maintain the chemotaxis gene program. These layers ensure that chemotaxis genes are expressed only when and where needed.
Cytoskeletal polarization and directional motility
In simple terms: The cell reorganizes its skeleton and physically crawls toward the signal.
Once receptors and transcriptional programs are engaged, the macrophage polarizes its actin cytoskeleton and forms protrusions that drive directional movement. This step is the actual execution of chemotaxis, and its positive regulation is what increases the rate and extent of migration. Macrophage polarization states, including M1(LPS+) and M2(LPS-) signatures, are associated with distinct migratory capacities and gene expression profiles, so the activation state of the cell influences how efficiently this cytoskeletal program runs. The outcome is measurable as increased macrophage infiltration in tissues such as atherosclerotic plaques and tumors.
Tissue-level consequences and feedback
In simple terms: More macrophages arrive, and they change the tissue they enter.
The endpoint of positive regulation is a higher number of macrophages at the target site, which then remodel the local microenvironment. In solid tumors, cooperation between constitutive and inducible chemokines enables T-cell engraftment and immune attack, showing that macrophage recruitment is embedded in a broader immune cell trafficking network. In metabolic and cardiovascular disease, excessive recruitment contributes to injury, as seen in myocardial ischemia/reperfusion and atherosclerosis models. Bioinformatics and Mendelian randomization analyses have also linked macrophage-related inflammatory pathways to non-alcoholic fatty liver disease and heart failure, underscoring the systemic relevance of this process.
Key Genes Involved in GO:0010759 positive regulation of macrophage chemotaxis
The following genes and proteins have been experimentally implicated in positive regulation of macrophage chemotaxis or in the recruitment programs that depend on it.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCL2 | Chemokine ligand that recruits CCR2-positive monocytes and macrophages | Central node in tumor and inflammatory macrophage recruitment; target of STAT3/CCL2/IL-6 axis studies |
| CCR2 | G-protein-coupled receptor for CCL2 on macrophages | Mediates chemokine sensing and directional migration; key chemotaxis receptor |
| CSF1 | Growth factor ligand for CSF1R that promotes macrophage recruitment and survival | Axis is druggable; CSF1R inhibitors reprogram tumor-associated macrophages |
| CSF1R | Receptor tyrosine kinase for CSF1 and IL-34 | Pharmacological target (pexidartinib) that alters macrophage infiltration and T-cell recruitment |
| IL34 | Cytokine ligand that signals through CSF1R-related complexes | Drives macrophage recruitment and polarization in myocardial ischemia/reperfusion injury |
| NFKB1 | Transcription factor downstream of IL-34 signaling | Mediates inflammatory gene expression linked to macrophage recruitment |
| STAT3 | Transcription factor in cancer cell-macrophage crosstalk | Regulates CCL2 and IL-6 expression that positively regulates macrophage chemotaxis |
| IL6 | Cytokine that amplifies inflammatory recruitment loops | Part of the STAT3/CCL2/IL-6 axis in bladder cancer progression |
| SPOP | E3 ubiquitin ligase adaptor downregulated in bladder cancer | Its loss promotes cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 |
| VEZF1 | Transcription factor regulating SPOP expression | Upstream regulator of the SPOP-STAT3-CCL2 axis |
| EZH2 | Histone H3K27 methyltransferase | Regulates apoptotic and inflammatory responses in sepsis-induced AKI, affecting macrophage behavior |
| MERRICAL | Long non-coding RNA epigenetic regulator | Deficiency abrogates macrophage chemotaxis and diabetes-associated atherosclerosis |
| PTPRC | Pan-leukocyte marker (CD45) | Used to identify recruited macrophage populations in tissues |
| CD68 | Macrophage marker | Common readout of macrophage infiltration in tumor and injury models |
| ITGAM | Integrin alpha-M (CD11b) involved in adhesion and migration | Supports macrophage motility and tissue infiltration |
| CCL5 | Chemokine contributing to immune cell recruitment | Part of constitutive and inducible chemokine cooperation in tumors |
| CXCL9 | Chemokine associated with T-cell and macrophage recruitment | Linked to immune attack in solid tumors |
| CXCL10 | Chemokine associated with immune cell trafficking | Linked to T-cell engraftment and immune attack in solid tumors |
How Is positive regulation of macrophage chemotaxis Regulated?
Positive regulation of macrophage chemotaxis is controlled at multiple levels. Extracellularly, chemokine availability and receptor expression set the recruitment threshold, as shown by the cooperation between constitutive and inducible chemokines in solid tumors. Growth-factor signaling through CSF1R and IL-34 provides an amplification loop that can be blocked pharmacologically. Intracellularly, transcription factors such as STAT3 and NF-kB drive expression of chemokines and inflammatory mediators that sustain recruitment. Epigenetic regulators, including the histone methyltransferase EZH2 and the long non-coding RNA MERRICAL, maintain the chromatin and RNA scaffolds required for chemotaxis gene expression. Finally, macrophage polarization state influences migratory capacity, with M1 and M2 signatures associated with distinct gene expression programs.
positive regulation of macrophage chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPOP | Bladder cancer progression via STAT3/CCL2/IL-6 axis | SPOP knockout or overexpression in bladder cancer cells co-cultured with macrophages |
| EZH2 | Sepsis-induced acute kidney injury | EZH2 conditional knockout or inhibitor-treated mouse AKI models |
| IL34 | Myocardial ischemia/reperfusion injury | IL-34 knockout or neutralizing antibody in mouse I/R models |
| MERRICAL | Diabetes-associated atherosclerosis | MERRICAL knockout in diabetic ApoE-deficient mice |
| CSF1R | Sarcoma tumor microenvironment | CSF1R inhibitor pexidartinib in sarcoma models with T-cell infiltration readouts |
Cancer progression and tumor immune contexture
Positive regulation of macrophage chemotaxis is co-opted by tumors to build an immunosuppressive microenvironment. In bladder cancer, SPOP downregulation promotes cancer cell-macrophage crosstalk via the STAT3/CCL2/IL-6 axis, enhancing macrophage recruitment and supporting progression. Cooperation between constitutive and inducible chemokines enables T-cell engraftment and immune attack in solid tumors, showing that macrophage trafficking is part of a broader chemokine network that can be therapeutically modulated. CSF1R inhibition with pexidartinib reprograms tumor-associated macrophages and stimulates T-cell infiltration in sarcoma, demonstrating that blocking positive regulation of macrophage chemotaxis can shift the immune balance.
Sepsis-associated acute kidney injury
In sepsis-induced acute kidney injury, inflammatory macrophage responses contribute to tissue damage. The histone H3K27 methyltransferase EZH2 regulates apoptotic and inflammatory responses in this setting, linking epigenetic control of macrophage behavior to kidney injury severity. Because positive regulation of macrophage chemotaxis determines how many macrophages reach the kidney, targeting this process may reduce inflammatory injury.
Cardiovascular and metabolic disease
Interleukin-34-NF-kB signaling aggravates myocardial ischemia/reperfusion injury by facilitating macrophage recruitment and polarization, directly implicating positive regulation of macrophage chemotaxis in cardiac injury. In diabetes-associated atherosclerosis, deficiency of the long non-coding RNA MERRICAL abrogates macrophage chemotaxis, reducing plaque burden. Bioinformatics and Mendelian randomization analyses have further linked macrophage-related inflammatory pathways to non-alcoholic fatty liver disease and heart failure, supporting a broader cardiometabolic role.
From positive regulation of macrophage chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for macrophage chemotaxis? | CRISPR knockout in macrophage cell lines or primary macrophages followed by Transwell migration |
| Does a specific point mutation alter chemokine receptor signaling? | CRISPR point-mutation knock-in of the receptor or signaling gene |
| Can a tagged protein be used to track chemotaxis machinery? | Tagged knock-in of the gene of interest in macrophages |
| Does overexpression of a chemokine or receptor increase recruitment? | CRISPR overexpression or lentiviral overexpression in cancer cells or macrophages |
| Which genes causally drive macrophage recruitment in a tumor? | CRISPR library screening in co-culture or in vivo tumor models |
| How does loss of an epigenetic regulator affect chemotaxis? | Knockout of lncRNA or chromatin modifier followed by RNA-seq and migration assays |
How to Study the positive regulation of macrophage chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell migration assay | Number of macrophages migrating toward a chemoattractant | Quantifying positive regulation of chemotaxis in vitro |
| Flow cytometry | Macrophage abundance and polarization markers | Measuring tissue infiltration in tumors and injury models |
| Immunohistochemistry | Spatial distribution of macrophages in tissue | Linking chemotaxis to pathology in kidney, heart, and tumor tissues |
| RNA-seq | Transcriptional programs associated with chemotaxis | Identifying downstream genes and polarization signatures |
| Bioinformatics / Mendelian randomization | Causal inference from human genetic and expression data | Linking macrophage pathways to NAFLD and heart failure |
| CRISPR knockout | Loss-of-function effect on chemotaxis | Testing whether a gene is required for macrophage recruitment |
| CRISPR knock-in / overexpression | Gain-of-function or tagged protein behavior | Testing point mutations or tracking proteins in migration |
| Co-culture assays | Cancer cell-macrophage crosstalk | Dissecting STAT3/CCL2/IL-6 signaling in bladder cancer |
Transwell and chemotaxis assays
Transwell migration assays remain the standard method to quantify positive regulation of macrophage chemotaxis. Macrophages are placed in the upper chamber and a chemoattractant such as CCL2 in the lower chamber; the number of migrated cells reflects the rate and extent of chemotaxis. This approach has been used to demonstrate that MERRICAL deficiency abrogates macrophage chemotaxis in atherosclerosis models and to assess macrophage recruitment in tumor studies.
Flow cytometry and immunohistochemistry
Flow cytometry with markers such as CD68, CD11b, and CD45 quantifies macrophage infiltration in tissues and can distinguish M1 versus M2 polarization states. Immunohistochemistry provides spatial information about where macrophages accumulate, which is critical for linking chemotaxis to tissue pathology in models of kidney injury, cardiac injury, and cancer.
Transcriptomics and bioinformatics
RNA-seq of macrophages or whole tissues reveals the gene expression programs downstream of chemotaxis regulators. Bioinformatics and Mendelian randomization analyses have been used to link macrophage-related inflammatory pathways to non-alcoholic fatty liver disease and heart failure. Comparing M1(LPS+) and M2(LPS-) signatures provides a framework for interpreting how polarization states intersect with migratory capacity.
Genetic perturbation and co-culture systems
CRISPR knockout, knock-in, and overexpression models allow causal testing of candidate genes. Co-culture of cancer cells with macrophages has been used to show that SPOP downregulation promotes macrophage recruitment via the STAT3/CCL2/IL-6 axis, and CSF1R inhibition studies demonstrate pharmacological modulation of macrophage recruitment in sarcoma. These systems are essential for distinguishing correlation from causation in GO:0010759 research.
How CRISPR Can Be Used to Study GO:0010759 positive regulation of macrophage chemotaxis
Knockout
CRISPR knockout is used to delete candidate genes such as chemokine receptors, epigenetic regulators, or lncRNAs and then measure macrophage chemotaxis. For example, loss of the lncRNA MERRICAL abrogates macrophage chemotaxis and diabetes-associated atherosclerosis, demonstrating a causal requirement. Knockout of chromatin modifiers such as EZH2 can reveal how epigenetic state controls inflammatory macrophage behavior in kidney injury.
Point Mutation
Point-mutation knock-in allows researchers to test specific residues in chemokine receptors or signaling intermediates without deleting the entire gene. This is valuable for dissecting the STAT3/CCL2/IL-6 axis, where phosphorylation or binding-site mutations can separate recruitment from other functions. Such models help determine whether a specific signaling event is required for positive regulation of macrophage chemotaxis.
Knock-in
Tagged knock-in of genes such as CCR2 or CSF1R enables live-cell imaging and biochemical tracking of the chemotaxis machinery. Knock-in reporters can also be used to monitor transcriptional activation of chemotaxis genes in real time. These models complement functional migration assays and provide spatial and temporal resolution.
Overexpression
CRISPR overexpression or lentiviral overexpression of chemokines such as CCL2 or growth factors such as CSF1 can increase macrophage recruitment and test sufficiency. Overexpression of SPOP pathway components has been used to show that the STAT3/CCL2/IL-6 axis drives cancer cell-macrophage crosstalk. Overexpression models are also useful for testing whether a candidate gene is sufficient to enhance chemotaxis in otherwise low-recruitment settings.
How EDITGENE Supports positive regulation of macrophage chemotaxis Research
Researchers studying positive regulation of macrophage chemotaxis-related genes often need to determine whether a candidate gene is causally involved in macrophage recruitment or merely correlated with it. EDITGENE provides the CRISPR tools and bioinformatics support required to move from candidate lists to validated mechanisms.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of macrophage chemotaxis research.
Frequently Asked Questions About positive regulation of macrophage chemotaxis
What is GO:0010759 positive regulation of macrophage chemotaxis?
GO:0010759 is a Gene Ontology biological process term defined as any process that increases the rate, frequency, or extent of macrophage chemotaxis, which is the directed movement of a macrophage in response to an external stimulus.
What genes are involved in positive regulation of macrophage chemotaxis?
Key genes include CCL2, CCR2, CSF1, CSF1R, IL34, STAT3, IL6, SPOP, VEZF1, EZH2, and the long non-coding RNA MERRICAL, based on published studies of macrophage recruitment.
How is macrophage chemotaxis positively regulated?
It is positively regulated by chemokine-receptor signaling such as CCL2/CCR2, growth-factor signaling through CSF1R and IL-34, transcription factors such as STAT3 and NF-kB, and epigenetic regulators including EZH2 and MERRICAL.
Why is positive regulation of macrophage chemotaxis important in cancer?
In cancer, it drives tumor-associated macrophage recruitment, which can create an immunosuppressive microenvironment; blocking it with CSF1R inhibitors can reprogram macrophages and stimulate T-cell infiltration.
What diseases are linked to macrophage chemotaxis?
Published work links it to sepsis-associated acute kidney injury, bladder cancer, myocardial ischemia/reperfusion injury, diabetes-associated atherosclerosis, and metabolic conditions such as NAFLD and heart failure.
How do you measure positive regulation of macrophage chemotaxis?
Common methods include Transwell migration assays, flow cytometry for macrophage markers, immunohistochemistry, and RNA-seq to profile chemotaxis gene programs.
What is the role of CCL2 in macrophage chemotaxis?
CCL2 is a chemokine that binds CCR2 on macrophages and recruits them to sites of inflammation or tumor growth; it is a central node in the STAT3/CCL2/IL-6 axis in bladder cancer.
Can CRISPR be used to study macrophage chemotaxis?
Yes. CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models are widely used to test causal roles of genes in macrophage recruitment and migration.
What is the role of CSF1R in macrophage recruitment?
CSF1R is a receptor tyrosine kinase for CSF1 and IL-34 that promotes macrophage recruitment and survival; its inhibitor pexidartinib reprograms tumor-associated macrophages and stimulates T-cell infiltration in sarcoma.
How does MERRICAL affect macrophage chemotaxis?
MERRICAL is a long non-coding RNA epigenetic regulator whose deficiency abrogates macrophage chemotaxis and reduces diabetes-associated atherosclerosis, showing it is required for the chemotaxis program.
Conclusion
GO:0010759 positive regulation of macrophage chemotaxis is a central biological process that controls how efficiently macrophages are recruited to inflamed, injured, or malignant tissues. Its molecular basis spans chemokine-receptor signaling, growth-factor amplification, transcription factor activity, and epigenetic licensing, with CCL2/CCR2, CSF1/CSF1R, IL-34, STAT3, EZH2, and MERRICAL as experimentally supported nodes. Because dysregulation of this process contributes to cancer progression, kidney injury, cardiac injury, and atherosclerosis, it is a high-value target for mechanistic and therapeutic research. CRISPR-based knockout, knock-in, and overexpression models combined with migration assays and transcriptomics provide a rigorous path to identify causal regulators and translate them into new interventions.
References
- 1. Li B et al.. 2023. Histone H3K27 methyltransferase EZH2 regulates apoptotic and inflammatory responses in sepsis-induced AKI.. Theranostics 13(6):1860-1875 PMID: 37064878
- 2. Orecchioni M et al.. 2019. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages.. Front Immunol 10:1084 PMID: 31178859
- 3. Dangaj D et al.. 2019. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.. Cancer Cell 35(6):885-900.e10 PMID: 31185212
- 4. Li M et al.. 2024. SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1.. Theranostics 14(17):6543-6559 PMID: 39479456
- 5. Fujiwara T et al.. 2021. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.. Mol Cancer Ther 20(8):1388-1399 PMID: 34088832
- 6. Zhuang L et al.. 2023. Interleukin-34-NF-κB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization.. EBioMedicine 95:104744 PMID: 37556943
- 7. Zhang Y et al.. 2024. Non-alcoholic fatty liver disease and heart failure: A comprehensive bioinformatics and Mendelian randomization analysis.. ESC Heart Fail 11(6):4185-4200 PMID: 39143741
- 8. Chen J et al.. 2024. Deficiency of lncRNA MERRICAL abrogates macrophage chemotaxis and diabetes-associated atherosclerosis.. Cell Rep 43(3):113815 PMID: 38428421
